MARKET NEWS

Hovione's Inhaler for High-Dose Delivery Earns Product Design Award
Guardion Health Sciences Announces Launch of Immuno-Supportive/Anti-Oxidant Complex
Biomarkers Heavily Used as Diagnostic Tools in COVID-19 Trials
Celsion Reports Sufficient Events Have Been Reached for the Second Interim Analysis of the Phase 3 OPTIMA Study
7 Hills Pharma Announces COVID-19 Vaccine Program Targeting At-Risk Elderly
Vir Biotechnology Announces VIR-2218 Demonstrates Dose-Dependent & Durable Reductions of  Hepatitis B Surface Antigen in Phase 1/2 Trial

  FEATURED EDITORIAL

  COMPANY PROFILE

Headquartered in Nashville,TN PMI BioPharma Solutions is a team of highly experienced life science experts providing rigorous research, pharmaceutical development, and clinical manufacturing services to clients in the pharmaceutical and biotechnology space. We pride ourselves on our abilities, integrity, and persistence in the face of challenge, and will exert maximal effort and ingenuity to achieve your goals. Click here for more.

  EXCLUSIVE ONLINE CONTENT

New COVID-19 Clinical Trial Supported by Octapharma USA

New COVID-19 Clinical Trial Supported by Octapharma USA

Octapharma USA is supporting a new investigator initiated clinical trial led by George Sakoulas, MD, of Sharp Memorial Hospital in San Diego, CA, focused on treating the most critical patients at the….

TFF Pharmaceuticals Announces R&D Collaboration for a Universal Influenza Vaccine

TFF Pharmaceuticals Announces R&D Collaboration for a Universal Influenza Vaccine

TFF Pharmaceuticals, Inc. recently announced that it has entered into a research collaboration with the University of Georgia’s Center for Vaccines and Immunology (CVI), along with….

HALIX Enters Collaboration for GMP Manufacturing of a COVID-19 Vaccine

HALIX Enters Collaboration for GMP Manufacturing of a COVID-19 Vaccine

HALIX B.V. has recently joined a consortium of partners under the guidance of the University of Oxford, to provide GMP manufacturing services supporting the large scale production of….

Samsung Bioepis Announces US Launch of Oncology Biosimilar for Early & Metastatic HER2-Overexpressing Breast Cancer & Metastatic Gastric Cancer

Samsung Bioepis Announces US Launch of Oncology Biosimilar for Early & Metastatic HER2-Overexpressing Breast Cancer & Metastatic Gastric Cancer

Samsung Bioepis Co., Ltd. recently announced today that ONTRUZANT (trastuzumab-dttb), a biosimilar of the reference biologic medicine HERCEPTIN (trastuzumab) for the treatment of….

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

April 29 – Formulation Development
May 6 – Prefilled Syringes